PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98010636 |
Filing Date: 05/24/2023 |
Input Field |
Entered |
TEAS Plus | YES |
---|---|
MARK INFORMATION | |
*MARK | TAZESTIG |
*STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | TAZESTIG |
*MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size, or color. |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Glaxo Group Limited |
*MAILING ADDRESS | 980 Great West Road |
*CITY | Brentford, Middlesex |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | England |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
TW89GS |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
*TYPE | private company limited by shares (prc) |
* STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED | United Kingdom |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
*INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders |
*FILING BASIS | SECTION 1(b) |
*FILING BASIS | SECTION 44(e) |
*FOREIGN REGISTRATION COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United Kingdom |
*FOREIGN REGISTRATION NUMBER |
UK00003026816 |
*FOREIGN REGISTRATION DATE |
10/18/2013 |
FOREIGN REGISTRATION EXPIRATION DATE |
10/17/2033 |
DATE FOREIGN REGISTRATION RENEWED (if applicable) |
05/23/2023 |
FOREIGN REGISTRATION FILE NAME(S) | |
ORIGINAL PDF FILE | reg-15251561-092021706_._ TAZESTIG_UK_REGISTATION.pdf |
CONVERTED PDF FILE(S) (1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\980\106\98010636\xml1\ FTK0003.JPG |
ORIGINAL PDF FILE | reg-15251561-092021706_._ TAZESTIG_UK_RENEWAL.pdf |
CONVERTED PDF FILE(S) (1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\980\106\98010636\xml1\ FTK0004.JPG |
STANDARD CHARACTERS OR EQUIVALENT |
YES |
ADDITIONAL STATEMENTS INFORMATION | |
*TRANSLATION (if applicable) |
|
*TRANSLITERATION (if applicable) |
|
*CLAIMED PRIOR REGISTRATION (if applicable) |
|
*CONSENT (NAME/LIKENESS) (if applicable) |
|
*CONCURRENT USE CLAIM (if applicable) |
|
ATTORNEY INFORMATION | |
NAME | Elizabeth K. Rucki |
ATTORNEY DOCKET NUMBER | 84230119 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | GSK |
INTERNAL ADDRESS | Legal Brand Protection |
STREET | 410 Blackwell Street |
CITY | Durham |
STATE | North Carolina |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 27701 |
PHONE | 919-353-8081 |
EMAIL ADDRESS | trademarks@gsk.com |
OTHER APPOINTED ATTORNEY | Christopher M. Hanes |
CORRESPONDENCE INFORMATION | |
NAME | Elizabeth K. Rucki |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Plus |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 250 |
*TOTAL FEES DUE | 250 |
*TOTAL FEES PAID | 250 |
SIGNATURE INFORMATION | |
* SIGNATURE | /Elizabeth K. Rucki/ |
* SIGNATORY'S NAME | Elizabeth K. Rucki |
* SIGNATORY'S POSITION | Attorney of record, Texas Bar member |
SIGNATORY'S PHONE NUMBER | 919-353-8081 |
* DATE SIGNED | 05/24/2023 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98010636 |
Filing Date: 05/24/2023 |
The applicant's current Correspondence Information: |
Elizabeth K. Rucki |
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|